IP Library Granted Patent US 11,167,129
Granted Patent B2
US 11,167,129 · App. 16/823,296 · Granted Nov 9, 2021

Neural stimulation dosing

Inventor: John Louis Parker (Artarmon, AU)
Assignee: Saluda Medical Pty Ltd
A61N1/0551A61N1/05A61N1/06A61N1/3605A61N1/36071A61N1/36146A61N1/36171A61N1/36175A61N1/36178A61N1/36185A61N1/37247A61N1/36021
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,167,129
App. No.
16/823,296
Granted
Nov 9, 2021
Kind
B2
Abstract

Applying therapeutic neural stimuli involves monitoring for at least one of sensory input and movement of a user. In response to detection of sensory input or user movement, an increased stimulus dosage is delivered within a period of time corresponding to a duration of time for which the detected sensory input or user movement gives rise to masking, the increased stimulus dosage being configured to give rise to increased neural recruitment.

Claims (25)

1. A method of applying therapeutic neural stimuli, the method comprising:

monitoring for at least one of sensory input and movement of a user; and

in response to detection of at least one of sensory input and a user movement, delivering an increased stimulus dosage within a period of time corresponding to a duration of time for which the detected sensory input or user movement gives rise to masking, the increased stimulus dosage being configured to give rise to increased neural recruitment.

2. The method of claim 1 , wherein the increased stimulus dosage is effected by increasing one or more of the stimulus amplitude, the stimulus pulse width and/or the stimulus frequency.

3. The method of claim 2 , wherein the increased stimulus dosage comprises a burst of high frequency stimuli.

4. The method of claim 1 wherein at times when neither sensory input nor movement is detected stimuli are delivered at a reduced dosage.

5. The method of claim 1 wherein at times when neither sensory input nor movement is detected no stimuli are delivered.

6. The method of claim 1 further comprising monitoring a cumulative stimulus dosage delivered to the user, and using the cumulative stimulus dosage as a basis to define a required stimulus regime either during or between movements in order to seek to deliver a desired total stimulus dosage.

7. The method of claim 1 wherein at least one of sensory input and movement of the user is detected by measuring neural activity upon the neural pathway.

8. The method of claim 7 wherein the measured neural activity comprises evoked neural responses resulting from electrical stimuli applied to the neural pathway.

9. The method of claim 8 wherein movement is detected when a change is detected in the neural response evoked from a given stimulus.

10. The method of claim 7 wherein the measured neural activity comprises non-evoked neural activity.

11. The method of claim 1 wherein movement of the user is detected by an accelerometer.

12. The method of claim 1 wherein the period of time within which the increased stimulus dosage is delivered is a predefined approximation of the duration of a typical human movement.

13. The method of claim 1 wherein the period of time for which the increased stimulus dosage is delivered is adaptively determined by performing the further step of detecting a cessation of sensory input or movement by the user, and in turn ceasing the delivery of the increased stimulus dosage.

14. The method of claim 1 wherein the increased stimulus dosage is delivered at select moments within the period of time.

15. A device for applying therapeutic neural stimuli, the device comprising:

at least one electrode configured to be positioned alongside a neural pathway of a user; and

a control unit configured to monitor for at least one of sensory input and movement of the user, and configured to deliver an increased stimulus dosage via the at least one electrode within a period of time corresponding to a duration of time for which the detected sensory input or user movement gives rise to masking, the increased stimulus dosage being configured to give rise to increased neural recruitment.

16. A method for effecting a neural blockade, the method comprising:

delivering a sequence of electrical stimuli to neural tissue, each stimulus configured at a level whereby at least at a given relative position of a stimulus electrode to the neural tissue a first stimulus of the sequence generates an action potential and whereby each subsequent stimulus alters a membrane potential of the neural tissue without causing depolarisation of the neural tissue nor evoking an action potential, each subsequent stimulus being delivered prior to recovery of the membrane potential of the neural tissue from a preceding stimulus such that the sequence of stimuli maintains the membrane potential in an altered range in which conduction of action potentials is hindered or prevented.

17. The method of claim 16 , wherein the blockade is effected by applying a sequence of supra-threshold stimuli, the first of which will evoke an action potential.

18. The method of claim 16 wherein the blockade is effected by applying a sequence of stimuli which are sub-threshold in a first posture, but which become supra-threshold at times when the user moves to a second posture.

19. The method of claim 16 wherein the sequence of stimuli is delivered at a frequency greater than 500 Hz.

20. The method of claim 19 wherein the sequence of stimuli is delivered at a frequency greater than 1 kHz.

Assignments (2)
SECURITY INTEREST Recorded Mar 14, 2025
From: SALUDA MEDICAL PTY LTD
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 070518/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2020
From: PARKER, JOHN LOUIS
To: SALUDA MEDICAL PTY LTD
Reel/Frame 052956/0875 →
Priority Claims (2)
AU 2014902897 · Jul 25, 2014 · national
AU 2015900912 · Mar 13, 2015 · national
Continuity (2)
Continuation 15327981
Related Publication 20200282208A1 · Sep 10, 2020
Cited By (4)
US 12,201,837 US 12,285,263 US 12,329,527 US 12,376,780